BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/10/2025 7:27:51 AM | Browse: 29 | Download: 0
Category |
Endocrinology & Metabolism |
Manuscript Type |
Letter to the Editor |
Article Title |
Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases
|
Manuscript Source |
Invited Manuscript |
All Author List |
Biao Qu, Zheng Li and Wei Hu |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
the Natural Science Research Project of Anhui Province |
2023AH053172 |
National Natural Science Foundation of Anhui Province |
2408085QH260 |
Projects of Administration of Traditional Chinese Medicine of Anhui Province |
2024CCCX082 |
National Natural Science Foundation Incubation Program of The Second Hospital of Anhui Medical University |
2022GMFY08 |
|
Corresponding Author |
Wei Hu, PhD, Professor, Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, Anhui Province, China. huwei@ahmu.edu.cn |
Key Words |
Diabetes; Atherosclerotic diseases; Metformin; Drug combination; Hypoglycemic agent; Hypolipidemic agent; Antioxidant agent |
Core Tip |
The hyperglycemic state can actually induce atherosclerosis development or further accelerate its progression, which leads to cardio-cerebrovascular diseases associated with high morbidity and mortality. As metformin is the preferred first-line drug to manage type 2 diabetes, metformin combined with either hypoglycemic agents, hypolipidemic agents, or systemic antioxidant/anti-inflammatory agents, have been investigated to provide additional vascular benefits. It is quite clear that such exploration can contribute to finding a better drug combination to mitigate diabetes-associated atherosclerotic diseases. |
Citation |
Qu B, Li Z, Hu W. Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases. World J Diabetes 2025; In press |
|
Received |
|
2024-08-20 06:21 |
|
Peer-Review Started |
|
2024-09-06 00:47 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-24 03:52 |
|
Revised |
|
2024-12-30 02:36 |
|
Second Decision |
|
2025-01-10 02:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-10 07:27 |
|
Articles in Press |
|
2025-01-10 07:27 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
ISSN |
1948-9358 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345